OVARIAN CANCER

This study tested whether adding a new drug called apatinib to a standard chemotherapy (etoposide) could help control advanced ovarian cancer that had stopped responding to platinum-based treatments. It involved 35 women to see if the combination was effective and safe. The goal …

This early-stage study tested a new nanoparticle form of a cancer drug called SNB-101 in 21 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and see how the body processes the drug. Patients received the…

This early-stage study tested a new immunotherapy drug called CUE-102 in patients with advanced colorectal, gastric, pancreatic, or ovarian cancer that had returned or spread after standard treatments. The main goals were to find a safe dose and see how the body processes the dru…

This study tested whether zafirlukast, a medication approved for asthma, could help control early signs of ovarian cancer returning. It involved a small group of patients whose cancer had relapsed based only on a blood marker (CA-125), not on scans. The goal was to see if the dru…

This study tested if it was safe to give an immunotherapy drug called nivolumab directly into the abdomen (intraperitoneal) after major surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. The main goal was to find the safest dose and see how well patients tolerat…

This early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers driven by specific KRAS or NRAS gene mutations. The goal was to see if the treatment is safe and can help clear tiny amounts of leftover cancer cells…

This study tested whether adding immunotherapy drugs to standard chemotherapy before surgery is safe and feasible for patients with advanced ovarian cancer. The trial involved 69 women with newly diagnosed, advanced ovarian, fallopian tube, or primary peritoneal cancer who were n…

This study tested whether adding a specialized geriatric care team to standard cancer treatment could help older patients. It involved 792 patients aged 70 and older with various advanced cancers. The goal was to see if this coordinated care approach improved survival and quality…

This study aimed to see if robot-assisted surgery is better than standard minimally invasive surgery for women with cervical, uterine, or ovarian cancer. It directly compared the two techniques in 386 patients, focusing on recovery time, complications, and quality of life after s…

This study tested whether adding an experimental drug called BD0801 to standard chemotherapy works better than chemotherapy alone for women with recurrent ovarian cancer that has stopped responding to platinum-based drugs. It involved 421 women whose cancer returned within 6 mont…

This study tested whether adding an experimental drug called TJ004309 to an existing immunotherapy (atezolizumab) could help control advanced cancers that have stopped responding to standard treatments. It involved 25 patients with specific types of advanced solid tumors, includi…

This first-in-human study tested a new oral drug called RP903 in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study focused on specific cancers, including ovar…

This study tested an experimental drug called mirvetuximab soravtansine for women with recurrent ovarian, peritoneal, or fallopian tube cancers that had previously responded well to platinum-based chemotherapy. The drug is designed like a 'smart bomb' to target and kill cancer ce…

This study aimed to find the most suitable first chemotherapy treatment for older, more vulnerable women with advanced ovarian cancer. It compared three different drug schedules to see which one was most successful at delivering a full course of treatment without causing severe s…

This early-stage trial tested a new oral drug, VS-6766, given alone and later combined with another drug called everolimus. The main goal was to find safe and tolerable dosing schedules for patients with advanced solid tumors or multiple myeloma that had stopped responding to sta…

This study tested a mobile app designed to help patients and doctors better manage advanced ovarian cancer. The app tracked patients' symptoms and health data, then used artificial intelligence to suggest care steps. It aimed to improve communication and help catch problems early…

This study tested an experimental drug called nirogacestat in patients with a rare type of ovarian cancer (granulosa cell tumor) that had returned after prior treatment. The goal was to see if the drug could shrink tumors and control the disease. The trial enrolled 53 adults whos…

This study tested a new oral medication called IMP4297 for women with advanced ovarian cancer that has a specific genetic change (BRCA mutation) and has stopped responding to at least two standard treatments. The main goal was to see if the drug could shrink tumors and control th…

This study tested a new drug called ZN-c3, both by itself and combined with an existing drug (niraparib), for women with advanced ovarian cancer that had stopped responding to platinum chemotherapy. The main goals were to find safe doses and see if the treatments could shrink tum…

This study tested a new combination of two drugs, NT-I7 and pembrolizumab, for people with advanced solid tumors that had returned or stopped responding to prior therapies. The main goals were to find a safe dose and see if the combination could shrink tumors in several hard-to-t…

This study tested a new drug called SL-172154, given alongside one of two standard chemotherapy drugs, in people with ovarian cancer that had stopped responding to platinum-based treatments. The main goals were to find a safe dose and see if the combinations showed early signs of…

This study tested the safety and effectiveness of combining two drugs, pembrolizumab and lenvatinib, in people with advanced solid tumors that had stopped responding to standard treatments. It involved 611 participants with cancers like triple-negative breast, ovarian, gastric, c…

This study tested whether a special green dye could help surgeons see the first lymph nodes that ovarian cancer might spread to. Researchers injected the dye into the ovaries of 48 women undergoing surgery for an ovarian mass. They used a special camera to see if the dye traveled…

This study tested new blood markers and calculation tools to help doctors better tell the difference between benign (non-cancerous) and malignant (cancerous) ovarian tumors before surgery. It involved 221 women who were scheduled for surgery to remove an ovarian cyst that was tho…

This study tested a new, non-invasive method to detect ovarian cancer earlier. Researchers used a special light technique on blood and tissue samples from 160 women with suspected or confirmed ovarian cancer. The goal was to see if this light test could accurately spot cancer and…

This study looked at two ways to help women with a strong family history or genetic risk of ovarian cancer. One group chose to have their ovaries and fallopian tubes removed as a preventive surgery. The other group chose intensive monitoring with frequent blood tests and ultrasou…

This study tested a new follow-up model for women who completed treatment for gynecologic cancers like ovarian, cervical, or endometrial cancer. It compared standard doctor visits to a program where nurses provided half the check-ups, focusing on emotional support and coaching pa…

This study tested whether adding a drug called aprepitant to the standard two-drug anti-nausea regimen works better to prevent nausea and vomiting caused by a common chemotherapy for gynecologic cancers. It involved 143 women with ovarian, cervical, or other gynecologic tumors wh…

This study tested whether giving a single low dose of the drug esketamine during surgery could help prevent depression afterwards in women with ovarian cancer. Researchers compared esketamine to a placebo (saltwater) in 568 patients to see if it reduced depressive symptoms, impro…

This study tested whether acupressure, a technique using finger pressure on specific body points, could help reduce severe fatigue in women who have completed treatment for ovarian cancer. It involved 171 survivors who reported significant fatigue. Researchers measured changes in…

This study tested an automated system to grow metastatic cancer cells from patients inside fertilized chicken eggs. The goal was to see if this method could reliably produce small tumors (xenografts) from patient samples, which could then be used for future drug testing and resea…

This study looked at how completely surgeons remove fallopian tubes during ovary removal surgery. Researchers examined tissue samples from 115 women to see if any fallopian tube tissue was left behind. The goal was to understand surgical quality and potentially create better trai…

This study observed how Chinese patients with ovarian or prostate cancer tolerated the cancer drug olaparib during regular medical care. Researchers followed 1,018 patients for 6-12 months to track side effects and treatment patterns. The goal was to understand the drug's safety …

This study tested different ways to encourage people to get genetic testing for breast and ovarian cancer risk. Researchers sent messages to patients and alerts to doctors to see which method worked best to get more people tested. The goal was to help more people, especially from…

This study tested two new methods to encourage people at higher risk for hereditary cancers to get recommended genetic testing. Over 800 participants in Michigan were randomly assigned to either use a special website, receive two coaching phone calls, or get standard information.…

This study tested a digital tool designed to help cancer survivors learn about and decide whether to get genetic testing for hereditary cancer risk. Researchers wanted to see if this smart technology was easy to use and if it encouraged more people to get tested. They compared th…

This study looked at cancer cells that break away from ovarian tumors and travel in the bloodstream. Researchers collected blood samples from 30 women with advanced ovarian cancer to examine these cells in detail. The goal was to understand if these cells can help predict how the…

This study looked at whether the cancer drug olaparib causes a folic acid (folate) deficiency in patients with advanced ovarian or breast cancer. Researchers wanted to see how often this happens and if giving patients a folic acid vitamin supplement could prevent the deficiency. …

This study aims to understand how common a specific protein marker called HER2 is in recurrent advanced endometrial, ovarian, and cervical cancers in Taiwan. Researchers will look back at the medical records and tissue samples of about 509 patients to see how many have high level…